^
    Back
    Association details:
    Biomarker:WNT5A overexpression + FZD2 overexpression
    Cancer:Prostate Cancer
    Drug:Xtandi (enzalutamide) (Androgen receptor inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AUA 2022
    Title:

    PD07-02 TARGETING WNT5A/FZD2 SIGNALING OVERCOMES RESISTANCE TO ENZALUTAMIDE IN ADVANCED PROSTATE CANCER

    Published date:
    04/09/2022
    Excerpt:
    Wnt5a and FZD2 are highly co-upregulated in CRPC patients and enzalutamide resistant C4-2B MDVR cells compared to parental C4-2B cells.
    DOI:
    10.1097/JU.0000000000002526.02